Delving into the Latest Updates on MELITAC 12.1 Peptide Vaccine(University of Virginia) with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide vaccine, Therapeutic vaccine

Synonyms-

Target-

Mechanism

Immunostimulants

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

MelanomaMelanoma, Cutaneous Malignant

Originator Organization

University of Virginia

Active Organization-

Inactive Organization

Oncovir, Inc.

University of Virginia

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 8002

Target: *****

Sequence Code 10439

Sequence Code 11442

Sequence Code 14810

Sequence Code 51341

Sequence Code 66966

Target: *****

Sequence Code 67028

Target: *****

Sequence Code 74015

Sequence Code 74097

Sequence Code 74128

Sequence Code 101057

Target: *****

Sequence Code 9162241

Target: *****

Sequence Code 1120173651

Target: *****

The purpose of this study is to learn the effects an experimental vaccine (MELITAC 12.1) combined with other substances called lipopolysaccharide (LPS; endotoxin), polyICLC, and Montanide ISA-51. The LPS, polyICLC, and Montanide ISA-51 are included with the vaccine to test whether they have an effect on the MELITAC 12.1 vaccine. The study will also look at whether the experimental vaccine and these drugs cause any changes to the immune system.

Start Date01 Oct 2012

Sponsor / Collaborator

University of Virginia

[+3]

NCT01264731 / CompletedPhase 1IIT

Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma

The purpose of the study is to determine 1) the safety of administration of topical 5% imiquimod cream with or without administration of a peptide-based vaccine in patients with cutaneous metastases of melanoma and 2) evaluate whether topical imiquimod at sites of melanoma metastasis, with or without vaccine, increases a) endothelial expression of E-selectin and b) T cell infiltration.

Start Date01 Jan 2011

Sponsor / Collaborator

University of Virginia

NCT00977145 / TerminatedPhase 1IIT

Evaluation of the Safety and Immunogenicity of Intratumoral Injection of Interferon Gamma During Vaccination in Patients With Subcutaneous or Cutaneous Metastases of Melanoma

The goals of this study are to evaluate 1) the safety of administration of intratumoral interferon gamma with a peptide-based vaccine, in patients with melanoma and 2) the biological effects of the vaccine. These include an examination of changes within the tumor following vaccination and the evaluation of T cell responses to the vaccine both in the blood and at the sight of tumor.

Start Date01 Nov 2009

Sponsor / Collaborator

University of Virginia

100 Clinical Results associated with MELITAC 12.1 Peptide Vaccine(University of Virginia)

Login to view more data

100 Translational Medicine associated with MELITAC 12.1 Peptide Vaccine(University of Virginia)

Login to view more data

100 Patents (Medical) associated with MELITAC 12.1 Peptide Vaccine(University of Virginia)

Login to view more data

100 Deals associated with MELITAC 12.1 Peptide Vaccine(University of Virginia)

Login to view more data